Journal of Neuroimmunology
Volume 220, Issue 1 , Pages 52-63 , 30 March 2010

Rapamycin inhibits relapsing experimental autoimmune encephalomyelitis by both effector and regulatory T cells modulation

  • Marianna Esposito

      Affiliations

    • Clinical Neuroimmunology Unit, Department of Neuroscience, Institute of Experimental Neurology (INSPE), San Raffaele Scientific Institute DIBIT, Milan, Italy
    • ,
  • Francesca Ruffini

      Affiliations

    • Clinical Neuroimmunology Unit, Department of Neuroscience, Institute of Experimental Neurology (INSPE), San Raffaele Scientific Institute DIBIT, Milan, Italy
    • ,
  • Matteo Bellone

      Affiliations

    • Department of Oncology, Cancer Immunotherapy and Gene Therapy Program (CIGTP), San Raffaele Scientific Institute DIBIT, Milan, Italy
    • ,
  • Nicola Gagliani

      Affiliations

    • Telethon Institute for Gene Therapy (TIGET), San Raffaele Scientific Institute DIBIT, Milan, Italy
    • ,
  • Manuela Battaglia

      Affiliations

    • Telethon Institute for Gene Therapy (TIGET), San Raffaele Scientific Institute DIBIT, Milan, Italy
    • Diabetes Research Institute (DRI), San Raffaele Scientific Institute DIBIT, Milan, Italy
    • ,
  • Gianvito Martino

      Affiliations

    • Neuroimmunology Unit, Department of Neuroscience, Institute of Experimental Neurology (INSPE), San Raffaele Scientific Institute DIBIT, Milan, Italy
    • ,
  • Roberto Furlan

      Affiliations

    • Clinical Neuroimmunology Unit, Department of Neuroscience, Institute of Experimental Neurology (INSPE), San Raffaele Scientific Institute DIBIT, Milan, Italy
    • Corresponding Author InformationCorresponding author. Clinical Neuroimmunology Unit, Institute of Experimental Neurology (INSPE), Division of Neuroscience, San Raffaele Scientific Institute, Via Olgettina 58, 20132 Milano, Italy. Tel.: +39 02 26434867; fax: +39 02 26434855.

Received 26 October 2009 ,Revised 5 January 2010 ,Accepted 5 January 2010.

References 

  1. Abraham RT, Wiederrecht GJ. Immunopharmacology of rapamycin. Annu. Rev. Immunol. 1996;14:483–510
  2. Allan SE, C.S.Q. , Crellin NK, Passerini L, Steiner TS, Bacchetta R, et al. Activation-induced FOXP3 in human T effector cells does not suppress proliferation or cytokine production. Int. Immunol. 2007;19:345–354
  3. Annacker O, P.-A.R. , Burlen-Defranoux O, Barbosa TC, Cumano A, Bandeira A. CD25+CD4+ T cells regulate the expansion of peripheral CD4 T cells through the production of IL-10. J. Immunol. 2001;166:3008–3018
  4. Annacker O, C.J.L. , Malmstrom V, Uhlig HH, Bourne T, Johansson-Lindbom B, et al. Essential role for CD103 in the T cell-mediated regulation of experimental colitis. J. Exp. Med. 2005;202:1051–1061
  5. Battaglia M, S.A. , Roncarolo MG. Rapamycin selectively expands CD4+CD25+Foxp3+ regulatory T cells. Blood. 2005;105:4743–4748
  6. Sharma R, Sung SS, Abaya CE, Ju AC, Fu SM, Ju ST. IL-2 regulates CD103 expression on CD4+ T cells in Scurfy mice that display both CD103-dependent and independent inflammation. J. Immunol. 2009;183:1065–1073
  7. Battaglia M, S.A. , Draghici E, Migliavacca B, Gregori S, Bonifacio E, et al. Induction of tolerance in type 1 diabetes via both CD4+CD25+ T regulatory T cells and T regulatory type 1 cells. Diabetes. 2006;55:1571–1580
  8. Bensinger SJ, W.P.T. , Zhang J, Carroll M, Parsons R, Rathmell JC, et al. Distinct IL-2 receptor signaling pattern in CD4+CD25+ regulatory T cells. J. Immunol. 2004;172:5287–5296
  9. Branisteanu DD, Mathieu C, Bouillon R. Synergism between sirolimus and 1, 25-dihydroxyvitamin D3 in vitro and in vivo. J. Neuroimmunol. 1997;79:138–147
  10. Butti E, Bergami A, Recchia A, Brambilla E, Del Carro U, Amadio S, et al. IL4 gene delivery to the CNS recruits regulatory T cells and induces clinical recovery in mouse models of multiple sclerosis. Gene Ther. 2008;15:504–515
  11. Carlson RP, B.W.L. , Caccese RG, Warner LM, Sehgal SN. Effects of orally administered rapamycin in animal models of arthritis and other autoimmune diseases. Ann. N. Y. Acad. Sci. 1993;685:86–113
  12. Colombetti S, Basso V, Mueller DL, Mondino A. Prolonged TCR/CD28 engagement drives IL-2-independent T cell clonal expansion through signaling mediated by the mammalian target of rapamycin. J. Immunol. 2006;176:2730–2738
  13. Dardalhon V, Awasthi A, Kwon H, Galileos G, Gao W, Sobel RA, et al. IL-4 inhibits TGF-beta-induced Foxp3+ T cells and, together with TGF-beta, generates IL-9+ IL-10+ Foxp3(−) effector T cells. Nat. Immunol. 2008;9:1347–1355
  14. Duplan V, B.G. , Heslan JM, Bruand C, Dutartre P, Mars LT, et al. LF 15-0195 treatment protects against central nervous system autoimmunity by favoring the development of Foxp3-expressing regulatory CD4 T cells. J. Immunol. 2006;176:839–847
  15. Fehervari Z, Sakaguchi S. Development and function of CD25+CD4+ regulatory T cells. Curr. Opin. Immunol. 2004;16:203–208
  16. Fontenot JD, Gavin MA, Rudensky AY. Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat. Immunol. 2003;4:330–336
  17. Gavin MA, T.T.R. , Houston E, DeRoos P, Ho WY, Stray-Pedersen A, et al. Single-cell analysis of normal and Foxp3-mutant human T cells: FOXP3 expression without regulatory T cell development. Proc. Natl. Acad. Sci. U. S. A. 2006;103:6659–6664
  18. Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science. 2003;299:1057–1061
  19. Izcue A, Coombes JL, Powrie F. Regulatory T cells suppress systemic and mucosal immune activation to control intestinal inflammation. Immunol. Rev. 2006;212:256–271
  20. Kahan BD, Camardo JS. Rapamycin: clinical results and future opportunities. Transplantation. 2001;72:1181–1193
  21. Kappos L, Barkhof F, Desmet A. The effect of oral temsirolimus on new magnetic resonance imaging scan lesions, brain atrophy, and the number of relapses in multiple sclerosis: results from a randomized, controlled, clinical trial. J. Neurol. 2005;252:S46
  22. Kennedy MK, T.L.J. , Dal Canto MC, Tuohy VK, Lu ZJ, Trotter JL, et al. Inhibition of murine relapsing experimental autoimmune encephalomyelitis by immune tolerance to proteolipid protein and its encephalitogenic peptides. J. Immunol. 1990;144:909–915
  23. Kim JM, Rudensky A. The role of the transcription factor Foxp3 in the development of regulatory T cells. Immunol. Rev. 2006;212:86–98
  24. Korn T, R.J. , Gao W, Bettelli E, Awasthi A, Petersen TR, et al. Myelin-specific regulatory T cells accumulate in the CNS but fail to control autoimmune inflammation. Nat. Med. 2007;13:423–431
  25. Kroenke MA, Segal BM. Th17 and Th1 responses directed against the immunizing epitope, as opposed to secondary epitopes, dominate the autoimmune repertoire during relapses of experimental autoimmune encephalomyelitis. J. Neurosci. Res. 2007;85:1685–1693
  26. Lehmann J, H.J. , De la Rosa M, Maszyna F, Kretschmer U, Krenn V, et al. Expression of the integrin alphaEbeta7 identifies unique subsets of CD25+ as well as CD25− regulatory T cells. Proc. Natl. Acad. Sci. U. S. A. 2002;99:13031–13036
  27. Levings MK, S.R. , Roncarolo MG. Human CD25+CD4+ T regulatory cells suppress naive and memory T cell proliferation and can be expanded in vitro without loss of function. J. Exp. Med. 2001;193:1295–1302
  28. Luke PP, Deng JP, O'Brien CA, Everest M, Hall AV, Chakrabarti S, et al. Alteration in CD45RBhi/CD45RBlo T-cell ratio following CD45RB monoclonal-antibody therapy occurs by selective deletion of CD45RBhi effector cells. Transplantation. 2003;76:400–409
  29. Mason D, Powrie F. Control of immune pathology by regulatory T cells. Curr. Opin. Immunol. 1998;10(6):649–655
  30. McGeachy MJ, S.L.A. , Anderton SM. Natural recovery and protection from autoimmune encephalomyelitis: contribution of CD4+CD25+ regulatory cells within the central nervous system. J. Immunol. 2005;175:3025–3032
  31. Neuhaus O, k.B.C. , Hartung HP. Immunosuppressive agents in multiple sclerosis. Am. Soc. Exp. Neurotherap. 2007;4:654–660
  32. O'Connor RA, M.K.H. , Anderton SM. The inflamed central nervous system drives the activation and rapid proliferation of Foxp3+ regulatory T cells. J. Immunol. 2007;179:958–966
  33. O'Connor RA, Prendergast CT, Sabatos CA, Lau CW, Leech MD, Wraith DC, et al. Cutting edge: Th1 cells facilitate the entry of Th17 cells to the central nervous system during experimental autoimmune encephalomyelitis. J. Immunol. 2008;181:3750–3754
  34. Olivares-Villagomez D, W.A.K. , Wang Y, Lafaille JJ. Repertoire requirements of CD4+ T cells that prevent spontaneous autoimmune encephalomyelitis. J. Immunol. 2000;164:5499–5507
  35. Pluchino S, Zanotti L, Rossi B, Brambilla E, Ottoboni L, Salani G, et al. Neurosphere-derived multipotent precursors promote neuroprotection by an immunomodulatory mechanism. Nature. 2005;436:266–271
  36. Powrie F, L.M.W. , Mauze S, Caddle LB, Coffman RL. Phenotypically distinct subsets of CD4+ T cells induce or protect from chronic intestinal inflammation in C.B-17 scid mice. Int. Immunol. 1993;5:1461–1471
  37. Powrie F, Correa-Oliveira R, Mauze S, Coffman RL. Regulatory interactions between CD45RBhigh and CD45RBlow CD4+ T cells are important for the balance between protective and pathogenic cell-mediated immunity. J. Exp. Med. 1994;179:589–600
  38. Read S, M.V. , Powrie F. Cytotoxic T lymphocyte-associated antigen 4 plays an essential role in the function of CD25+CD4+ regulatory cells that control intestinal inflammation. J. Exp. Med. 2000;192:295–302
  39. Roncarolo MG, Gregori S. Is FOXP3 a bona fide marker for human regulatory T cells?. Eur. J. Immunol. 2008;38:925–927
  40. Sakaguchi S, S.N. , Asano M, Itoh M, Toda M. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J. Immunol. 1995;155:1151–1164
  41. Sehgal SN. Sirolimus: its discovery, biological properties, and mechanism of action. Transplant. Proc. 2003;35:7S–14S
  42. Stephens LA, Mason D. CD25 is a marker for CD4+ thymocytes that prevent autoimmune diabetes in rats, but peripheral T cells with this function are found in both CD25+ and CD25− subpopulations. J. Immunol. 2000;165:3105–3110
  43. Thornton AM, Shevach EM. CD4+CD25+ immunoregulatory T cells suppress polyclonal T cell activation in vitro by inhibiting interleukin 2 production. J. Exp. Med. 1998;188:287–296
  44. Wei G, Wei L, Zhu J, Zang C, Hu-Li J, Yao Z, et al. Global mapping of H3K4me3 and H3K27me3 reveals specificity and plasticity in lineage fate determination of differentiating CD4+ T cells. Immunity. 2009;30:155–167
  45. Zhang X, R.J. , Ochi H, Frenkel D, Kuchroo VK, Weiner HL. Recovery from experimental allergic encephalomyelitis is TGFb dependent and associated with increases in CD4+LAP+ and CD4+CD25+ T cells. Int. Immunol. 2006;18:495–503
  46. Zhou L, L.J.E. , Chong MM, Ivanov II, Min R, Victora GD, et al. TGF-beta-induced Foxp3 inhibits T(H)17 cell differentiation by antagonizing RORgammat function. Nature. 2008;453:236–240

PII: S0165-5728(10)00006-8

doi: 10.1016/j.jneuroim.2010.01.001

Journal of Neuroimmunology
Volume 220, Issue 1 , Pages 52-63 , 30 March 2010

Article Tools

* Image Usage & Resolution